三博脑科 reported revenue of ¥0.97B for the period ended 2026-06-30, +17.4% year on year. Net income was ¥0.02B, a 1.9% net margin on a 22.4% gross margin. The largest revenue line is 医疗服务 at 76% of the total. Free cash flow for the period was ¥0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.97B | +17.4% |
| Gross profit | ¥0.22B | — |
| Operating income | ¥0.06B | — |
| Net income | ¥0.02B | -74.4% |
| Gross margin | 22.4% | Net margin 1.9% |
| Revenue Q/Q | +18.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 医疗服务 | ¥0.73B | 75.5% |
| 药品 | ¥0.23B | 24.0% |
| 其他(补充) | ¥0.00B | 0.5% |
| 供应链 | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.75B | 77.6% |
| SG&A | ¥0.13B | 13.3% |
| Tax & other | ¥0.04B | 3.9% |
| Item | Amount |
|---|---|
| Total assets | ¥3.91B |
| Total liabilities | ¥1.26B |
| Shareholders' equity | ¥2.65B |
| Equity / assets | 67.8% |
| Operating cash flow | ¥0.08B |
| Capital expenditure | ¥0.06B |
| Free cash flow | ¥0.02B |
| Cash conversion (OCF / net income) | 642% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
美硕科技 ・ 新巨丰 ・ 富乐德 ・ 东利机械 ・ 卓创资讯 ・ 远翔新材 ・ 川宁生物 ・ 华如科技 ・ 真兰仪表 ・ 朗坤科技 ・ 西测测试 ・ 美利信
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies